Antev Asset Acquisition (Schedule of contingent consideration) (Details) - Antev Limited [Member]	Aug. 29, 2025 USD ($) $ / shares
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 1.52
Cash paid | $	$ 2,970,166
Advanced Prostate Cancer - Phase 2 success or registration [Member]
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 1.47
Cash paid | $	$ 5,333,200
Advanced Prostate Cancer - Phase 2 success or registration [Member] | Common Stock [Member]
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 2
Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member]
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 5.52
Cash paid | $	$ 19,999,500
Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member] | Common Stock [Member]
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 7.5
FDA NDA approval - Hormone therapy for prostate cancer [Member]
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 5.52
Cash paid | $	$ 20,000,000
FDA NDA approval - Hormone therapy for prostate cancer [Member] | Maximum [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent consideration | $	$ 20,000,000
FDA NDA approval - AUR prevention [Member]
Business Combination, Contingent Consideration [Line Items]
Business combination, price per share | $ / shares	$ 5.52
Cash paid | $	$ 20,000,000
FDA NDA approval - AUR prevention [Member] | Maximum [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent consideration | $	$ 20,000,000